Nevro Corp. (NYSE:NVRO)‘s stock had its “buy” rating reiterated by research analysts at B. Riley in a research note issued to investors on Friday.

Several other equities analysts have also weighed in on NVRO. Piper Jaffray Cos. began coverage on shares of Nevro Corp. in a research report on Friday, July 22nd. They set an “overweight” rating for the company. Wells Fargo & Co. began coverage on shares of Nevro Corp. in a research report on Tuesday, July 12th. They set an “outperform” rating for the company. William Blair restated an “outperform” rating on shares of Nevro Corp. in a research report on Monday, July 18th. Finally, Bank of America Corp. began coverage on shares of Nevro Corp. in a research report on Monday, August 8th. They set a “buy” rating for the company. Two research analysts have rated the stock with a hold rating and eleven have given a buy rating to the stock. The company presently has an average rating of “Buy” and a consensus target price of $76.75.

Nevro Corp. (NYSE:NVRO) traded down 0.49% during trading on Friday, reaching $95.48. 114,817 shares of the company were exchanged. The company’s market capitalization is $2.72 billion. The firm’s 50-day moving average is $93.56 and its 200 day moving average is $74.38. Nevro Corp. has a one year low of $36.51 and a one year high of $100.83.

Several institutional investors have recently added to or reduced their stakes in the stock. Springbok Capital Management LLC raised its position in Nevro Corp. by 303.8% in the first quarter. Springbok Capital Management LLC now owns 2,685 shares of the company’s stock worth $151,000 after buying an additional 2,020 shares during the period. JPMorgan Chase & Co. raised its position in Nevro Corp. by 1.4% in the first quarter. JPMorgan Chase & Co. now owns 852,758 shares of the company’s stock worth $47,976,000 after buying an additional 11,695 shares during the period. Cormorant Asset Management LLC raised its position in Nevro Corp. by 82.9% in the first quarter. Cormorant Asset Management LLC now owns 485,386 shares of the company’s stock worth $27,308,000 after buying an additional 220,000 shares during the period. UBS Asset Management Americas Inc. raised its position in Nevro Corp. by 31.5% in the first quarter. UBS Asset Management Americas Inc. now owns 7,100 shares of the company’s stock worth $399,000 after buying an additional 1,700 shares during the period. Finally, Geode Capital Management LLC raised its position in Nevro Corp. by 2.2% in the first quarter. Geode Capital Management LLC now owns 89,667 shares of the company’s stock worth $5,044,000 after buying an additional 1,907 shares during the period.

About Nevro Corp.

Nevro Corp. is a medical device company. The Company has developed and commercialized a neuromodulation platform for the treatment of chronic pain. The Company’s Senza system is a spinal cord stimulation (SCS) system that delivers its HF10 therapy. HF10 therapy is designed to deliver neuromodulation solutions for treating chronic pain.

5 Day Chart for NYSE:NVRO

Receive News & Ratings for Nevro Corp. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nevro Corp. and related companies with MarketBeat.com's FREE daily email newsletter.